The Patient From Hell

Well maybe I should give the full title: The Patient from Hell: How I Worked with My Doctors to Get the Best of Modern Medicine and How You Can Too written by noted climatologist Stephen H. Schneider. Normally I dutifly read books by patients but as a whole they don't tend to hit the mark. In this book I'm happy to report: this is a book any lymphoma patient will want to read. When Schneider was diagnosed with Mantle Cell Non-Hodgkin's lymphoma (MCL), he took advocating cutting edge treatment to a new level (hence the patient from hell moniker). Actually his approach makes sense and it will to you too - called Bayesian updating, in a nutshell it is going along a course and using the latest data to update the course. This is in contrast to many medical center treatments where they know your start point (your exact diagnosis) and the final outcome they want (a fixed treatment protocol) but refuse to deviate from defined protocol.



Well written (with co-author Janica Lane), it provides patients of all types (including all lymphomas) with methodologies you, your caregivers/advocates, and your medical team can use to maximize the effctiveness of your treatments.



I intend to pass the book on to my wife who was my caregiver and advocate - she will relate strongly with Schneider's wife, Terry Root, who helped him immensely with both his care and in researching cutting-edge treatment information.



I highly recommend reading this book.



Amazon currently has a 34% discount on it too - that helps alot :-)

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap